PREX2 and non-small cell lung carcinoma: However, the tumor-specific reliance on the PREX2-AHCYL1 axis, as evidenced by different MEK/ERK and PI3K/AKT signaling response in NL20 and NSCLC cells after AHCYL1 knockdown, suggests a potential therapeutic window.